Circle Pharma, Inc.

Circle Pharma, Inc. is revolutionizing macrocycle drug development with a unique approach to designing bioavailable macrocyclic peptide therapeutics. The company was founded in 2012 and has garnered support from prominent investors including Pfizer, Inc., Mission Bay Capital, LLP, and ShangPharma Investment Group Limited for its seed funding, before securing additional funding through Series B and Series C rounds from The Column Group and NextTech Invest respectively. The most recent milestone for Circle Pharma is its Series D investment announced on 3rd September 2024. Circle Pharma's focus lies in leveraging a computational structure-based design approach to target intracellular protein-protein interactions relevant in cancer therapy. Through the utilization of proprietary algorithms, the company develops a diverse range of virtual libraries of cell-permeable macrocyclic scaffolds, incorporating natural and non-natural backbone components to enhance target binding and permeability. With an emphasis on innovative molecular components and leveraging the founders' pioneering work, Circle Pharma is poised to make significant strides in the biotechnology, health care, and health and wellness sectors.